Novel Coronavirus update - Radixivir clinical trial starts in Wuhan
On the evening of February 6, a clinical trial of the antiviral drug Redecide was started at Wuhan Jinyintan Hospital.
Experts hope an experimental drug can be as effective against the novel coronavirus in people as it has been on cells in a controlled lab environment.
Clinical trials of the experimental drug Remdesivir have begun in Wuhan. The trial will include 453 critically ill patients and 308 with less severe symptoms.
Prior to January 31, an article in the New England Journal of Medicine described that a U.S. person with New Crown Pneumonia started to use Redecive on the evening of the 7th day of admission (11th day of illness). For treatment.
The next day, the patient's clinical condition improved. After stopping supplemental oxygen, the patient's oxygen saturation value increased to 94% to 96% when breathing ambient air.
The previous bilateral lower lobe rales no longer exist. In addition, his appetite also improved, with the exception of intermittent dry cough and snot, and other symptoms recovered.
However, Gilead issued a statement on January 31 stating: "Redesivir has not been approved for marketing in any country and its safety and effectiveness have not been proven.
Redesivir is a drug under investigation and does not target the new coronavirus. (2019-nCoV). " At the same time, the statement said, "We are also conducting appropriate laboratory tests on Redecive with 2019-nCoV virus samples." Professor Cao Bin introduced that Radixivir is a drug under investigation by Gilead Corporation in the United States.
Experts hope an experimental drug can be as effective against the novel coronavirus in people as it has been on cells in a controlled lab environment.
Clinical trials of the experimental drug Remdesivir have begun in Wuhan. The trial will include 453 critically ill patients and 308 with less severe symptoms.
Prior to January 31, an article in the New England Journal of Medicine described that a U.S. person with New Crown Pneumonia started to use Redecive on the evening of the 7th day of admission (11th day of illness). For treatment.
The next day, the patient's clinical condition improved. After stopping supplemental oxygen, the patient's oxygen saturation value increased to 94% to 96% when breathing ambient air.
The previous bilateral lower lobe rales no longer exist. In addition, his appetite also improved, with the exception of intermittent dry cough and snot, and other symptoms recovered.
However, Gilead issued a statement on January 31 stating: "Redesivir has not been approved for marketing in any country and its safety and effectiveness have not been proven.
Redesivir is a drug under investigation and does not target the new coronavirus. (2019-nCoV). " At the same time, the statement said, "We are also conducting appropriate laboratory tests on Redecive with 2019-nCoV virus samples." Professor Cao Bin introduced that Radixivir is a drug under investigation by Gilead Corporation in the United States.
It has shown good antiviral activity against SARS coronavirus and MERS coronavirus in previous cell and animal experiments. Desivir Clinical Trial for Ebola Coronavirus Infection. Currently, there is a lack of effective antiviral drugs for patients with new types of coronavirus infections, and we look forward to the clinical performance of redecive.
On February 2, the official website of the China-Japan Friendship Hospital announced that the hospital will lead a clinical study of Rhedivevir in the treatment of new coronavirus pneumonia in Wuhan. The total sample size is expected to be 270 cases. Ended on the 27th.
On February 2, the official website of the China-Japan Friendship Hospital announced that the hospital will lead a clinical study of Rhedivevir in the treatment of new coronavirus pneumonia in Wuhan. The total sample size is expected to be 270 cases. Ended on the 27th.
No comments